Across TCGA pan-cancer cohorts, MT-ND6 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MT-ND6 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher MT-ND6 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MT-ND6 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

GBM and HNSC are the cancer types where MT-ND6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.605	0.922	.041	1	view →
HNSC	OS	Median	IV	1.000	0.805	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: MT-ND6 tumor-vs-normal RNA expression · all MT-ND6 data types